Jpmorgan Chase & CO Gt Biopharma, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.22 - $0.28 $9 - $12	-43 Reduced 72.88%	16 $0
Q3 2023 Nov 14, 2023	SELL	$0.24 - $0.35 $609 - $888	-2,538 Reduced 97.73%	59 $0
Q2 2023 Aug 11, 2023	BUY	$0.22 - $0.55 $567 - $1,419	2,581 Added 16131.25%	2,597 $0
Q2 2022 Aug 11, 2022	SELL	$1.64 - $3.11 $13,648 - $25,881	-8,322 Reduced 99.81%	16 $0
Q1 2022 May 11, 2022	BUY	$2.6 - $3.3 $3,913 - $4,966	1,505 Added 22.03%	8,338 $24,000
Q3 2021 Nov 12, 2021	BUY	$6.68 - $15.26 $45,644 - $104,271	6,833 New	6,833 $46,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $81.7M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.